Meeting Starts In
Advance Promising Targets for Familial & Sporadic Disease, Validate Sensitive Markers of Disease Progression & Enhance Innovative Trial Design to Transform ALS Drug Development
Meaningful progress in establishing causative genetic mutations and environmental factors implicated in ALS disease progression and advances in validating emerging biomarkers to evaluate treatment response has meant that the landscape for drug development in ALS is exploding. With exciting new targets, revised inclusion criteria, and opportunities to implement digital biomarkers for remote and sensitive monitoring, we have never been closer to bringing meaningful therapies to patients.
Uniting industry experts dedicated to accelerating effective therapeutic approaches, the ALS Drug Development Summit is the definitive industry forum sharing cross-industry insight to rapidly advance life-changing ALS therapeutics.
From dissecting exciting progress in small molecules and gene therapy to clarifying sensitive primary outcome measures beyond ALSFRS-R, join industry experts from Biogen, Eli Lilly, Mitsubishi Tanabe Pharma, Sanofi, ProMIS Neurosciences, Cytokinetics, Brainstorm Cell Therapeutics and many more to drive progress towards slowed disease progression and improved outcomes in ALS.
Reviews From the Hanson Wade CNS Community:
“A fantastic opportunity to share learnings among an outstanding group of academic, industry and patient advocacy experts working toward a common goal of transformative therapies for neurodevelopmental disorders” Director, Biogen
"High quality speakers and multiple opportunities to meet the other participants. Highly informative and interactive" President, Creative Bio-Peptides Inc.
“This meeting is a remarkable opportunity to bring people together to focus on the most important research directions in ALS and share ideas for how to make these advances as rapidly as possible.” Chief, Division of ALS & Motor Neuron Diseases, Massachusetts General Hospital